Stockscreener 앱 받기
23.10
3.08%
0.69
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer? - TipRanks
IDEAYA Biosciences: Hold Rating Amid Key Pipeline Developments and Anticipated Clinical Milestones - TipRanks
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025 - MSN
IDEAYA Biosciences Inc Reports Q2 2025 Financial Results: Net Loss of $77.5 Million, EPS of -$0.88, and No Revenue - AInvest
Ideaya Biosciences Q2 EPS Beats Consensus, Sees Catalyst-Rich Period Ahead - AInvest
GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959 - TipRanks
Ideaya Biosciences shares rise 3.19% premarket after reporting Q2 net loss and positive trial data. - AInvest
IDEAYA Biosciences Reports Q2 2025 Financial Results - TipRanks
IDEAYA (IDYA) Q2 Net Loss Improves 27% - The Motley Fool
IDEAYA (IDYA) Q2 Net Loss Improves 27% - Nasdaq
IDEAYA Biosciences Enters ADC Market with Solid Tumor Focus - AInvest
IDEAYA Biosciences: Moving Into ADCs For Solid Tumors (NASDAQ:IDYA) - Seeking Alpha
Ideaya Biosciences earnings missed by $0.09, revenue topped estimates - Investing.com
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
IDEAYA Biosciences Reports Q2 GAAP EPS of -$0.88, Misses Expectations - AInvest
IDEAYA Biosciences's Q2 net loss widens as costs mount - MarketScreener
IDEAYA Reports Phase 2/3 Trial Data and Neoadjuvant Darovasertib Results - AInvest
IDEAYA Advances 6 Clinical Programs, Reports Massive $992M Cash Runway Through 2029 - Stock Titan
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - Ariva
Published on: 2025-08-05 04:17:11 - metal.it
Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study - TipRanks
Ideaya Biosciences shares rise 6.02% premarket as New Zealand shares down tracking Wall Street sell-off. - AInvest
What institutional investors are buying IDEAYA Biosciences Inc. stockCapitalize on proven trading setups - Jammu Links News
How many analysts rate IDEAYA Biosciences Inc. as a “Buy”Maximize portfolio growth with expert advice - Jammu Links News
How does IDEAYA Biosciences Inc. compare to its industry peersConsistent triple-digit returns - Jammu Links News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - cnhinews.com
What analysts say about IDEAYA Biosciences Inc. stockGet expert advice on portfolio optimization - Jammu Links News
Should I hold or sell IDEAYA Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
What makes IDEAYA Biosciences Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
What drives IDEAYA Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the risk reward ratio of investing in IDEAYA Biosciences Inc. stockGet alerts on the hottest stocks daily - Jammu Links News
How strong is IDEAYA Biosciences Inc. company’s balance sheetMarket-crushing stock picks - Jammu Links News
What catalysts could drive IDEAYA Biosciences Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News
How sentiment analysis helps forecast IDEAYA Biosciences Inc.Neural Network Based Equity Prediction System - Newser
IDEAYA Biosciences Awards Stock Options to New Employee - AInvest
Historical volatility pattern of IDEAYA Biosciences Inc. visualizedIntraday Signal Forecast for Fast Traders - Newser
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
IDEAYA Biosciences Awards $765K Worth of Stock Options to New Employee: Full Grant Details - Stock Titan
How to build a custom watchlist for IDEAYA Biosciences Inc.Consistent Gain Plan with AI Support - Newser
TD Cowen Bullish on Ideaya’s (IDYA) Oncology Pipeline - MSN
What is IDEAYA Biosciences Inc. company’s growth strategyPost Market Review For 2025 - jammulinksnews.com
Mizuho lowers Ideaya Biosciences stock price target to $43 on pipeline review - Investing.com Canada
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $43 - 富途牛牛
Mizuho Securities Maintains Buy Rating and $43 Price Target for IDEAYA Biosciences (IDYA) - AInvest
Will IDEAYA Biosciences Inc. bounce back from current supportRisk-Managed Swing Setup and Signal Analysis - Newser
Is IDEAYA Biosciences Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - metal.it
Applying Wyckoff theory to IDEAYA Biosciences Inc. stockSwing Setup With Technical Confirmation Explained - metal.it
Chart based analysis of IDEAYA Biosciences Inc. trendsAsset Allocation Summary With Future Outlook - Newser
Will IDEAYA Biosciences Inc. outperform the marketNext Day Momentum Stock Forecasting Report - Newser
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionFree Proven Entry Plan With Low Risk Trade - Newser
Will IDEAYA Biosciences Inc. stock benefit from AI tech trendsWatchlist Generator With Real-Time Entry - Newser
JPMorgan Chase & Co. Issues Positive Forecast for IDEAYA Biosciences (NASDAQ:IDYA) Stock Price - Defense World
0.24%
3.39%
자본화:
|
볼륨(24시간):